Conformational change as one of the earliest alterations of tau in Alzheimer's disease - PubMed (original) (raw)

Conformational change as one of the earliest alterations of tau in Alzheimer's disease

C L Weaver et al. Neurobiol Aging. 2000 Sep-Oct.

Abstract

Paired helical filaments (PHFs) found in Alzheimer's disease (AD) are mainly comprised of an abnormal form of tau (PHF-tau) that has undergone several post-translational modifications. Previous studies have shown that the monoclonal antibody MCI identifies a distinct conformation of tau in AD. We have assessed the temporal and spatial occurrence of the tau conformation recognized by MC1, and found its appearance in hippocampal neurons vulnerable to neurofibrillary tangle (NFT) formation in Braak Stage I and II cases. Electron microscopy has clearly demonstrated that this conformation precedes the formation of PHF. MC1 immunoaffinity chromatography also has identified a nonfilamentous, soluble pool of this abnormal tau. ELISA and immunoblotting have shown that this material is indistinguishable from that found in NFTs. This soluble component has the ability to self-assemble into PHFs in a concentration-dependent manner. Because the conformational change recognized by MCI appears before the assembly of and is found in PHF, but is not present in the normal brain, we suggest that the formation of the MCI epitope is one of the earliest pathological alterations of tau in AD.

PubMed Disclaimer

Cited by

The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice.
Brelstaff J, Ossola B, Neher JJ, Klingstedt T, Nilsson KP, Goedert M, Spillantini MG, Tolkovsky AM. Brelstaff J, et al. Front Neurosci. 2015 May 29;9:184. doi: 10.3389/fnins.2015.00184. eCollection 2015. Front Neurosci. 2015. PMID: 26074756 Free PMC article.
Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease.
Lilek J, Ajroud K, Feldman AZ, Krishnamachari S, Ghourchian S, Gefen T, Spencer CL, Kawles A, Mao Q, Tranovich JF, Jack CR, Mesulam MM, Reichard RR, Zhang H, Murray ME, Knopman D, Dickson DW, Petersen RC, Smith B, Ashe KH, Mielke MM, Nelson KM, Flanagan ME. Lilek J, et al. J Alzheimers Dis. 2023;92(1):241-260. doi: 10.3233/JAD-220848. J Alzheimers Dis. 2023. PMID: 36744338 Free PMC article.
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.
Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, Patterson C, Hutton M, Petrucelli L. Dickey CA, et al. J Neurosci. 2006 Jun 28;26(26):6985-96. doi: 10.1523/JNEUROSCI.0746-06.2006. J Neurosci. 2006. PMID: 16807328 Free PMC article.
Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh.
Rohn TT, Kokoulina P, Eaton CR, Poon WW. Rohn TT, et al. Int J Clin Exp Med. 2009 Nov 5;2(4):300-8. Int J Clin Exp Med. 2009. PMID: 20057974 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Conformational change as one of the earliest alterations of tau in Alzheimer's disease - PubMed (original) (raw)